It's How Medicine Should Be®


French German Italian Portuguese Russian

Major Depressive Disorder Adjunctive Therapy Investigational Medication Study

Clinical Trial Title: 
A Phase 3, Double-Blind, Placebo-Controlled Study of an Investigational Medication as Adjunctive Therapy in Major Depressive Disorder
Clinical Trial Protocol ID: 
Clinical Trial Investigator Name: 
Corey Goldstein, MD
Clinical Trial Protocol Description: 

This is an 18- to 19-week study in patients with major depressive disorder who have an inadequate response to certain other antidepressants. The study will include a one- to two-week screening period, followed by an eight-week, open-label period of treatment with an antidepressant, followed by an eight-week, double-blind treatment period with the investigational medication or placebo added to the antidepressant therapy, followed by a one-week safety follow-up period. A 26-week open-label extension study may also be available to those who complete the lead-in study.

Clinical Trial Eligibility Criteria: 

You may be eligible to participate in this study if you:

  • Are 18-65 years of age
  • Have major depressive disorder, with current episode lasting between two and 12 months
  • Have failure to an adequate trial of an antidepressant during the current depressive episode

You will be excluded from this study if you:

  • Have certain other diagnoses
  • Have a history of ECT and/or certain other treatments during the current episode or within 6 months of study
  • Have current, or history of, substance use or dependence
  • Have certain other medical conditions
  • Have current, or history of, cataracts, eye surgery, laser treatment

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. 

Clinical Trial Area: 
Mental Health Disorders
Contact Phone: 
(312) 942-6597
Contact Name: 
Treatment Research Center